This is a Phase II study designed to estimate the efficacy of weekly low-dose PEG-Intron in pediatric patients with CNS tumors, beginning 2-10 weeks after completion of radiation therapy. The endpoint of the trial is 2-year survival compared to historical controls who have received radiation alone. Patients undergo extensive imaging analysis. Accrual to this trial has been completed, patients are being followed for endpoint analyses, and biologic samples are being evaluated. All patients have tolerated the PEG-Intron therapy well, with no adverse events directly attributable to the study agent. Preliminary study results have been presented at the International Society of Pediatric Neuro-Oncology. We showed that patients receiving PEG-Intron have a median time to progression of 7 months compared to similar patients on recently completed consortia trials, who have a median time to progression of 4-5 months.
|Warren, Katherine E (2012) Diffuse intrinsic pontine glioma: poised for progress. Front Oncol 2:205|
|Warren, Katherine; Bent, Robyn; Wolters, Pamela L et al. (2012) A phase 2 study of pegylated interferon ?-2b (PEG-Intron(®)) in children with diffuse intrinsic pontine glioma. Cancer 118:3607-13|
|Ko, Christine; Kaushal, Aradhana; Hammoud, Dima A et al. (2012) Role of early postradiation magnetic resonance imaging scans in children with diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 83:1252-6|
|Steffen-Smith, Emilie A; Venzon, David J; Bent, Robyn S et al. (2012) Single- and multivoxel proton spectroscopy in pediatric patients with diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 84:774-9|